$Ocugen(OCGN)$ got approval from the Food and Drug Administration for the design of the company's Phase 3 study of regenerative cell therapy NeoCart. The therapy is being tested to repair lesions in the knee cartilage of adults.
$Ocugen(OCGN)$ got approval from the Food and Drug Administration for the design of the company's Phase 3 study of regenerative cell therapy NeoCart. The therapy is being tested to repair lesions in the knee cartilage of adults.
Comments